Рациональная фармакотерапия в кардиологии (Jan 2016)

NEW EVIDENCES OF POSSIBILITY OF OMEGA-3 ACIDS USE FOR MYOCARDIAL INFARCTION SECONDARY PREVENTION

  • A. I. Martinov,
  • V. L. Chomenko

DOI
https://doi.org/10.20996/1819-6446-2006-2-3-65-68
Journal volume & issue
Vol. 2, no. 3
pp. 65 – 68

Abstract

Read online

The metabolism, classification, biomedical implication and clinical application of polyunsaturated fatty acids (PUFAs) were analyzed. It was proved that PUFAs class omega-3 have positive effects on cardiovascular system. First of all, this is an antiarrhythmogenic action, which is accompanied by the increase in variability of heart rhythm. Omega-3 PUFAs cause the reduction in platelet activity and vasoactive mediator release (serotonin, thromboxane A2), vasodilatation, the reduction in inflammatory mediators release and endothelium permeability, the rising of endothelium dependent dilatation of vessels, the depression of vascular response on angiotensine П and noradrenalin. Omega-3 PUFAs are responsible for the reduction in blood pressure, the increase in erythrocytes elasticity, the fall of fibrinogen concentration and normalization of plasma lipid profile. Omega-3 PUFAs in large dozes show antiatherosclerotic effect. Clinical data showing that Omega-3 PUFAs increase in life time due to reduction in sudden death incidence were provided. It is suggested to use Omega-3 PUFAs (OMAKOR) for secondary prevention of ischemic heart disease and treatment of hypertriglyceridemia.

Keywords